Court overturns CMA’s excessive pricing drug fine

The UK’s Competition Appeal Tribunal has overturned a €101.5 million fine on Pfizer and Flynn Pharma for excessively pricing an epilepsy drug.

Get unlimited access to all Global Competition Review content